Breakthrough Therapies Driving the X-Linked Hypophosphatemia Market Forward According to a newly published market research report by 24LifeSciences, the global X-linked hypophosphatemia market was valued at USD 26.9 million in 2026 and is projected to reach USD 31.2 million by 2034, growing at a compound annual growth rate (CAGR) of 2.2% during the forecast period. X-linked hypophosphatemia (XLH), also known as vitamin D-resistant rickets, is a rare, inherited disorder characterized by renal phosphate wasting and impaired bone mineralization. This condition stems from mutations in the PHEX gene, leading to elevated levels of the hormone fibroblast growth factor 23 (FGF23), which disrupts phosphate reabsorption in the kidneys and reduces active vitamin D synthesis. The disease manifests through skeletal deformities, growth retardation, bone pain, and dental abnormalities, presenting a lifelong management challenge for patients and healthcare systems. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8996/x-linked-hypophosphatemia-market